RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients

RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients

Background. Since circulating tumor DNA (ctDNA) offers clear advantages as a minimally invasive method for tumor monitoring compared with tumor tissue, we aimed to evaluate genotyping ctDNA using a next-generation sequencing- (NGS-) based panel to identify the prognostic value of mutation status in...

Full description

Bibliographic Details
Main Authors:	Jiannan Yao, Wanchun Zang, Yang Ge, Nathaniel Weygant, Pan Yu, Lei Li, Guanhua Rao, Zhi Jiang, Rui Yan, Linjia He, Yang Yu, Mulan Jin, Gang Cheng, Guangyu An
Format:	Article
Language:	English
Published:	Hindawi Limited 2018-01-01
Series:	Canadian Journal of Gastroenterology and Hepatology
Online Access:	http://dx.doi.org/10.1155/2018/4248971

Similar Items

Perspectives in the Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer Patients
by: Gerardo Rosati, et al.
Published: (2021-03-01)

Targeting BRAF and RAS in Colorectal Cancer
by: Helene Bellio, et al.
Published: (2021-05-01)

Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta‐analysis
by: Lauren C. Bylsma, et al.
Published: (2020-02-01)

Precision Therapy of Metastatic Colorectal Cancer with RAS Mutation
by: ZOU Jiayun, et al.
Published: (2021-08-01)

First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis
by: Bobo Zheng, et al.
Published: (2019-03-01)

Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials
by: Yang Ge, et al.
Published: (2021-07-01)

The Role of BRAF in Metastatic Colorectal Carcinoma–Past, Present, and Future
by: Angela Djanani, et al.
Published: (2020-11-01)

Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer
by: Elisa Grassi, et al.
Published: (2021-06-01)

Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan
by: Tatsuki Ikoma, et al.
Published: (2021-05-01)

Evolution of RAS Mutational Status in Liquid Biopsies During First-Line Chemotherapy for Metastatic Colorectal Cancer
by: Susanne Klein-Scory, et al.
Published: (2020-07-01)

Incidence and prognostic factors in patents (pts) with mutant BRAF (mBRAF) metastatic colorectal cancer (mCRC) in Russia
by: M. Yu. Fedyanin, et al.
Published: (2021-06-01)

Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS‐mutant metastatic colorectal cancer
by: Elena Elez, et al.
Published: (2019-09-01)

The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer
by: Giuseppe Nicolò Fanelli, et al.
Published: (2020-01-01)

OPTIMIZATION OF METASTATIC COLORECTAL CANCER TREATMENT WITH RAS MUTATIONS
by: L. V. Bolotina
Published: (2015-02-01)

Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer
by: Chiara Guarini, et al.
Published: (2021-06-01)

Circulating Methylated DNA to Monitor the Dynamics of RAS Mutation Clearance in Plasma from Metastatic Colorectal Cancer Patients
by: Chiara Nicolazzo, et al.
Published: (2020-12-01)

Management of BRAF Gene Alterations in Metastatic Colorectal Cancer: From Current Therapeutic Strategies to Future Perspectives
by: Hiroyuki Takeda, et al.
Published: (2021-03-01)

Combination chemotherapy for metastatic colorectal cancer
by: Koehne Claus-Henning
Published: (2003-01-01)

RAS and BRAF mutations in cell‐free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested RAS wild‐type advanced colorectal cancer
by: Erik J. vanHelden, et al.
Published: (2019-11-01)

Complete response with fluorouracil and irinotecan with a BRAFV600E and EGFR inhibitor in BRAF-mutated metastatic colorectal cancer: a case report
by: Wang Z, et al.
Published: (2019-01-01)

RAS status and neoadjuvant chemotherapy impact CD8+ cells and tumor HLA class I expression in liver metastatic colorectal cancer
by: Fanny Ledys, et al.
Published: (2018-11-01)

Clinical Practice Use of Liquid Biopsy to Identify <i>RAS</i>/<i>BRAF</i> Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience
by: Pietro Paolo Vitiello, et al.
Published: (2019-10-01)

<i>KRAS</i> and <i>BRAF</i> Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study
by: Nuria Garcia-Carbonero, et al.
Published: (2020-01-01)

Study of Ras Mutations’ Prognostic Value in Metastatic Colorectal Cancer: STORIA Analysis
by: Alessandro Ottaiano, et al.
Published: (2020-07-01)

Prognostic importance of primary tumor location in RAS mutant metastatic colorectal cancer
by: Nadiye Akdeniz, et al.
Published: (2019-06-01)

Impact of RAS/RAF mutations on clinical and prognostic outcomes in metastatic colorectal cancer
by: Roya Dolatkhah, et al.
Published: (2021-01-01)

Association of emergence of new mutations in circulating tumuor DNA during chemotherapy with clinical outcome in metastatic colorectal cancer
by: Ning Jia, et al.
Published: (2021-07-01)

<em>BRAF</em> Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC Study
by: Leo Mas, et al.
Published: (2019-07-01)

Pharmacoeconomic-guided choice of systemic chemotherapy in metastatic colorectal cancer patients
by: M. Yu. Fedyanin, et al.
Published: (2017-09-01)

Assessment of activating mutations of FGFR2-RAS-BRAF and SMO in ameloblastoma
by: Pei-Hsuan Lu, et al.
Published: (2017)

Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing.
by: Kazuko Sakai, et al.
Published: (2015-01-01)

Cost-Effectiveness Analysis of Chemotherapy for Metastatic Colorectal Cancer
by: Er-Jung Hsueh, et al.
Published: (2014)

KRAS, NRAS, and BRAF Mutation Pattern in Metastatic Colorectal Cancer: A Study from Northwest Iran
by: Roya Dolatkhah, et al.
Published: (2019-08-01)

Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
by: S. Gattenlöhner, et al.
Published: (2009-01-01)

KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer – practical implications for the clinician
by: Afrăsânie Vlad-Adrian, et al.
Published: (2019-09-01)

Clinical significance of <it>BRAF </it>mutations in metastatic melanoma
by: Polsky David, et al.
Published: (2004-12-01)

Targeting mutant BRAF in colorectal cancer
by: Carroll David, et al.
Published: (2013-01-01)

THE HIGH ACTIVITY OF VECTIBIX IN PATIENTS WITH METASTATIC COLORECTAL CANCER WITH THE RAS WILD-TYPE GENE
by: N. N. Semenov
Published: (2015-02-01)

Clinico-pathological associations and concomitant mutations of the RAS/RAF pathway in metastatic colorectal cancer
by: Edoardo Isnaldi, et al.
Published: (2019-04-01)

Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation
by: Rossi L, et al.
Published: (2013-11-01)